Latest Articles
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter
Published: June 18, 2026, 2:24 p.m.
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years - MSN
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN
Published: June 8, 2026, 8:37 p.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org
Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org
Published: May 29, 2026, 11:56 p.m.
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations - CancerNetwork
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations CancerNetwork
Published: May 25, 2026, 1:56 p.m.
Endometriosis and ovarian cancer risk.
To critically evaluate the evidence linking endometriosis to ovarian cancer, with particular focus on endometrioid and clear cell histologic subtypes, and to inform risk stratification and patient counseling.
Published: May 12, 2026, midnight
Managing Progression After Immunotherapy in Endometrial Cancer - OncLive
Managing Progression After Immunotherapy in Endometrial Cancer OncLive
Published: May 5, 2026, 12:07 p.m.
High response rates in platinum-resistant ovarian cancer with immunotherapy agents - MSN
High response rates in platinum-resistant ovarian cancer with immunotherapy agents MSN
Published: April 20, 2026, 8:14 a.m.
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times
Published: April 17, 2026, 12:30 p.m.
Link copied to clipboard!